10477-83-5

Usage

Uses

Used in Pharmaceutical Research:
(1E)-1-(4-methylbenzylidene)-2-(4-nitrophenyl)hydrazine is utilized as a key intermediate in pharmaceutical research for its potential to exhibit biological activities such as anti-inflammatory, antimicrobial, and antiviral properties. Its unique structure allows it to be a candidate for the development of new drugs targeting a range of health conditions.
Used in Organic Synthesis:
In the field of organic synthesis, (1E)-1-(4-methylbenzylidene)-2-(4-nitrophenyl)hydrazine serves as a valuable building block for the creation of more complex organic compounds. Its reactivity and structural features make it suitable for use in the synthesis of various organic molecules with potential applications in different industries.
Further studies are necessary to fully explore the pharmacological potential and the mechanism of action of (1E)-1-(4-methylbenzylidene)-2-(4-nitrophenyl)hydrazine, which could lead to its integration into a broader spectrum of applications within the medical and chemical sectors.

Upstream product

• 104-87-0 4-methyl-benzaldehyde 
• 100-16-3 4-nitrophenylhydrazone 
• 100-00-5 4-chlorobenzonitrile 

Downstream Products

• 77722-19-1 [1-(4-Nitro-phenyl)-5-phenyl-3-p-tolyl-4,5-dihydro-1H-pyrazol-4-yl]-phenyl-methanone 
• 77722-13-5 1-(4-Nitro-phenyl)-5-phenyl-3-p-tolyl-1H-pyrazole-4-carbonitrile 
• 77721-90-5 α-(phenylsulfonyl)-p-tolualdehyde p-nitrophenylhydrazone 
• 77722-17-9 2-(4-Nitro-phenyl)-5-p-tolyl-3,4-dihydro-2H-pyrazole-3-carbonitrile 
• 77721-86-9 [(4-Nitro-phenyl)-hydrazono]-p-tolyl-acetonitrile 
• 104-87-0 4-methyl-benzaldehyde 
• 345291-50-1 (4-methyl-α-nitro-benzylidene)-(4-nitro-phenyl)-hydrazine 
• 24652-19-5 4-Methyl-benzoic acid N'-acetyl-N'-(4-nitro-phenyl)-hydrazide 

Relevant academic research and scientific papers

A straightforward synthesis of some fused aza-arenes via nucleophilic displacement of a ring hydrogen atom in nitroarenes by aromatic hydrazone anions

6-Nitroquinoline 6 undergoes direct cyclocondensation with aromatic aldehyde hydrazones 9 in the presence of sodium hydride in DMF at low temperature, giving the corresponding 3-aryl-1H-pyrazolo[3,4-f]quinolines 10 and/or 3-aryl[1,2,4]triazino[6,5-f]quino

Structure-Based Rational Design of Novel Inhibitors Against Fructose-1,6-Bisphosphate Aldolase from Candida albicans

Class II fructose-1,6-bisphosphate aldolases (FBA-II) are attractive new targets for the discovery of drugs to combat invasive fungal infection, because they are absent in animals and higher plants. Although several FBA-II inhibitors have been reported, none of these inhibitors exhibit antifungal effect so far. In this study, several novel inhibitors of FBA-II from C. albicans (Ca-FBA-II) with potent antifungal effects were rationally designed by jointly using a specific protocols of molecular docking-based virtual screening, accurate binding-conformation evaluation strategy, synthesis and enzymatic assays. The enzymatic assays reveal that the compounds 3c, 3e-g, 3j and 3k exhibit high inhibitory activity against Ca-FBA-II (IC50 50 value of 2.7 μM. Importantly, the compounds 3f, 3g, and 3l possess not only high inhibitions against Ca-FBA-II, but also moderate antifungal activities against C. glabrata (MIC80 = 4-64 μg/mL). The compounds 3g, 3l, and 3k in combination with fluconazole (8 μg/mL) displayed significantly synergistic antifungal activities (MIC80 0.0625 μg/mL) against resistant Candida strains, which are resistant to azoles drugs. The probable binding modes between 3g and the active site of Ca-FBA-II have been proposed by using the DOX (docking, ONIOM, and XO) strategy. To our knowledge, no FBA-II inhibitors with antifungal activities against wild type and resistant strains from Candida were reported previously. The positive results suggest that the strategy adopted in this study are a promising method for the discovery of novel drugs against azole-resistant fungal pathogens in the future.